hit counter
Aytu BioScience, Inc. (AYTU) Stock News Sentiment & Price - Sentifly
AYTU - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aytu BioScience, Inc. (AYTU)

USA
Biotechnology
NASDAQ
AYTU Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AYTU Latest news
PRNewsWire
Neutral
ALERT: Rowley Law PLLC is Investigating Potential Breaches of Fiduciary Duty by the Aytu BioPharma, Inc. Board of Directors
2021-10-04 16:49

NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating a potential breach of fiduciary duty claim involving the board of directors of Aytu BioPharma, Inc. (NASDAQ: AYTU). If you are a stockholder of Aytu BioPharma, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at:  http://www.rowleylawpllc.com/investigation/aytu /.

Accesswire
Neutral
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
2021-09-30 08:01

(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23 rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m.

Benzinga
Negative
Recap: Aytu BioPharma Q4 Earnings
2021-09-29 07:05

Aytu BioPharma(NASDAQ:AYTU) stock fell by 8.33% on Tuesday after the company reported its Q4 earnings results on Monday, September 27, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

Seeking Alpha
Neutral
Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript
2021-09-27 19:36

Aytu Biopharma, Inc.'s (AYTU) CEO Josh Disbrow on Q4 2021 Results - Earnings Call Transcript

Accesswire
Neutral
Aytu BioPharma Reports Fourth Quarter and Full-Year Fiscal 2021 Financial Results
2021-09-27 16:01

Quarterly net revenue increased 74% sequentially to $23.5M; 138% year-over-year to $65.6M Ended quarter with approximately $50M in cash, cash equivalents and restricted cash Planned pivotal study for AR101 in Vascular Ehlers-Danlos Syndrome (VEDS) to begin in 1H22; scientific advisory board recently formed Initiation of Healight randomized, sham-controlled study planned near-term; recently published positive and validating data for UV-A light technology platform Future revenue growth expected from newly consolidated sales force and product portfolio supported by fully integrated and expanding RxConnect patient support program Management to host live conference call and webcast today at 4:30 p.m. ET ENGLEWOOD, CO / ACCESSWIRE / September 27, 2021 / Aytu BioPharma, Inc. (Nasdaq:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for the fiscal fourth quarter and full-year ended June 30, 2021.

Accesswire
Neutral
Aytu BioPharma to Report Fourth Quarter and Full Year Fiscal 2021 Results and Provide Business Update on September 27, 2021
2021-09-23 08:00

ENGLEWOOD, CO / ACCESSWIRE / September 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that it will host a conference call and live webcast on September 27, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the fourth quarter and fiscal year 2021 and provide an overview of its business and growth strategy.

Accesswire
Neutral
Aytu BioPharma to Present at Upcoming September Investor Conferences
2021-09-07 08:00

ENGLEWOOD, CO / ACCESSWIRE / September 7, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that Josh Disbrow, Chairman and Chief Executive Officer will present during two upcoming investor conferences in September: H. C. Wainwright 23 rd Annual Global Investment Conference: On demand presentation available beginning Monday, September 13, 2021 at 7 a.m.

Accesswire
Neutral
Aytu BioPharma Announces Publication of Data Demonstrating Ultraviolet-A Light Reduces Cellular Cytokine Release from Human Endotracheal Cells Infected with Coronavirus
2021-07-27 08:05

ENGLEWOOD, CO / ACCESSWIRE / July 27, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, announced today that data from a laboratory study evaluating the ultraviolet A light used in the Healight™ endotracheal catheter technology was published in the peer reviewed journal Photodiagnosis and Photodynamics Therapy. "These latest in vitro findings continue to build upon the body of scientific evidence supporting the potential of this UVA platform technology and may help to explain the observed effects of Healight in SARS-CoV-2.

Zacks Investment Research
Positive
Implied Volatility Surging for Aytu Biopharma (AYTU) Stock Options
2021-07-07 09:46

Investors need to pay close attention to Aytu Biopharma (AYTU) stock based on the movements in the options market lately.

Accesswire
Neutral
Aytu BioPharma Announces Peer-Reviewed Publication of Clinical Results from Healight(TM) Pilot Study
2021-06-28 08:50

Results Indicate That Endotracheal UVA Light Catheter Therapy is Associated with Significant Reduction in SARS-CoV-2 Viral Load and Improvement in Clinical Outcomes in Mechanically Ventilated COVID-19 Patients ENGLEWOOD, CO / ACCESSWIRE / June 28, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that data from the first in-human, open label, clinical trial studying the safety and effectiveness of ultraviolet A (UVA) light endotracheal catheter therapy was published online on June 26, 2021 in the peer-reviewed journal Advances In Therapy. The UVA light catheter technology utilized in this study is the basis of Aytu BioPharma's Healight™ medical device which has been exclusively licensed worldwide for all endotracheal and nasopharyngeal applications.

Loading more news...